ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B Turnover 34.18%
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ABVX icon
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
REPL icon
326
CALL
Replimune Group
REPL
$1.07B
– –
-100,000
Closed -$765K –
RGNX icon
327
Regenxbio
RGNX
$454M
– –
-44,416
Closed -$372K –
SDGR icon
328
Schrodinger
SDGR
$1.87B
– –
-101,500
Closed -$1.15M –
SGRY icon
329
Surgery Partners
SGRY
$1.94B
– –
-20,000
Closed -$238K –
SLNO icon
330
DELISTED
Soleno Therapeutics
SLNO
– –
-46,830
Closed -$1.57M –
SNDX icon
331
Syndax Pharmaceuticals
SNDX
$1.21B
– –
-17,500
Closed -$409K –
SRRK icon
332
Scholar Rock
SRRK
$4.82B
– –
-407,273
Closed -$20M –
SRZN icon
333
Surrozen
SRZN
$279M
– –
-12,000
Closed -$350K –
SXT icon
334
Sensient Technologies
SXT
$5.65B
– –
-15,000
Closed -$1.3M –
TERN icon
335
CALL
DELISTED
Terns Pharmaceuticals
TERN
– –
-200,000
Closed -$10.5M –
TERN icon
336
DELISTED
Terns Pharmaceuticals
TERN
– –
-914,699
Closed -$48.2M –
TFX icon
337
Teleflex
TFX
$5.22B
– –
-21,186
Closed -$2.53M –
STLN icon
338
Starling Oncology
STLN
$663M
– –
-50,000
Closed -$154K –
UNH icon
339
UnitedHealth
UNH
$355B
– –
-5,501
Closed -$1.49M –
VRDN icon
340
Viridian Therapeutics
VRDN
$2.08B
– –
-304,422
Closed -$5.95M –
VRTX icon
341
Vertex Pharmaceuticals
VRTX
$126B
– –
-15,075
Closed -$6.73M –
AVBP icon
342
ArriVent BioPharma
AVBP
$799M
– –
-141,814
Closed -$3.27M –
GUTS icon
343
CALL
Fractyl Health
GUTS
$54.1M
– –
-119,048
Closed -$654K –
KYTX icon
344
Kyverna Therapeutics
KYTX
$351M
– –
-22,428
Closed -$194K –
QTTB icon
345
Q32 Bio
QTTB
$238M
– –
-35,000
Closed -$225K –
RBRK icon
346
Rubrik
RBRK
$23.6B
– –
-4,900
Closed -$240K –
BIOA icon
347
BioAge Labs
BIOA
$249M
– –
-135,560
Closed -$2.37M –
UPB icon
348
Upstream Bio Inc
UPB
$187M
– –
-35,000
Closed -$315K –
BSAAU icon
349
BEST SPAC I Acquisition Corp Unit
BSAAU
– –
-100,000
Closed -$1.04M –
10 11 12 13
14

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.